US 12233106
C-type natriuretic peptide variants to treat skeletal dysplasia in children
granted A61KA61K38/1709A61K38/2242
Quick answer
US patent 12233106 (C-type natriuretic peptide variants to treat skeletal dysplasia in children) held by BIOMARIN PHARMACEUTICAL INC. expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- BIOMARIN PHARMACEUTICAL INC.
- Grant date
- Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 14
- CPC classes
- A61K, A61K38/1709, A61K38/2242, A61K47/10, A61K47/12